2Seventy Bio Inc
NASDAQ:TSVT
2Seventy Bio Inc
Cash from Investing Activities
2Seventy Bio Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
2Seventy Bio Inc
NASDAQ:TSVT
|
Cash from Investing Activities
$80.8m
|
CAGR 3-Years
74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$20.8B
|
CAGR 3-Years
-107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-37%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$3.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.8B
|
CAGR 3-Years
-123%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$2.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-19%
|
|
2Seventy Bio Inc
Glance View
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.
See Also
What is 2Seventy Bio Inc's Cash from Investing Activities?
Cash from Investing Activities
80.8m
USD
Based on the financial report for Dec 31, 2024, 2Seventy Bio Inc's Cash from Investing Activities amounts to 80.8m USD.
What is 2Seventy Bio Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
74%
Over the last year, the Cash from Investing Activities growth was 84%. The average annual Cash from Investing Activities growth rates for 2Seventy Bio Inc have been 74% over the past three years .
You don't have any saved screeners yet